Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 14/20 | 0.77 |
| ▸ | ACE | P12821 | 6/20 | 0.76 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.76 |
| ▸ | MME | P08473 | 3/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917007 | 1.00 | GZMB (0.77) | GZMBACEACE2MMECASP3 | |
| SCHEMBL22687320 | 0.92 | GZMB (0.69) | GZMBACEACE2MMECASP3 | |
| SCHEMBL21186451 | 0.91 | GZMB (0.77) | GZMBACEACE2CASP3CASP8 | |
| SCHEMBL22687177 | 0.91 | GZMB (0.79) | GZMBACEACE2MME | |
| SCHEMBL22687113 | 0.91 | ACE (0.72) | GZMBACEACE2MME | |
| SCHEMBL22687188 | 0.91 | ACE (0.72) | GZMBACEACE2MME | |
| SCHEMBL22687186 | 0.91 | ACE (0.72) | GZMBACEACE2MME | |
| SCHEMBL22687344 | 0.91 | ACE (0.72) | GZMBACEACE2MME | |
| SCHEMBL5917192 | 0.89 | GZMB (0.73) | GZMBACEACE2MME | |
| SCHEMBL5917194 | 0.89 | GZMB (0.73) | GZMBACEACE2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060019945-A1 | Granzyme b inhibitors | CHAPMAN KEVIN T | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019945-A1 | Granzyme b inhibitors | GZMB, CTSB, SERPINB1 | GZMB 1/4885ACE 711/4885ACE2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.